Skip to content
DraconiticResearch
Search Sources API
197,578 studies31 sourcesUpdated 46 min ago
Peer-reviewedCC BY-NC-ND 4.0Journal of Translational Medicine

Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease

  • Xiwen Lei1
  • Rui Dong2
  • Lijuan Yin1
  • Zhenjie Wu3
  • Linhui Wang3
  • Miaoxia He1
  1. 1Department of Pathology, Changhai Hospital, Naval Medical University, 168 Changhai Rd. Building 17, Room 708, Shanghai, 200433 China
  2. 2Department of Nephrology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 China
  3. 3Department of Urology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai, 200433 China
Read full textPDFDOICite

Abstract

Background: Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical course, it presents significant management challenges in advanced or late-stage disease.

Main body of the abstract: This review presents current evidence regarding chRCC histopathology, emerging biomarkers, and proposed grading systems. We comprehensively analyze the molecular landscape, highlighting TP53 and PTEN mutations alongside characteristic chromosomal losses, while evaluating the role of epigenetic modifications and the immune microenvironment. Crucially, the paper details the mechanisms through which mitochondrial dysfunction and metabolic reprogramming drive chRCC pathogenesis. By assessing contemporary clinical trials, this work underscores the necessity for novel therapeutic interventions and the collection of large-scale prospective data to address current gaps in treatment.

Conclusion: A precision oncology framework for chRCC should prioritize reproducible diagnosis, cautious biomarker validation, and prospective rare-tumor trials to refine risk stratification and management.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08668-z.

Related

  1. Precision surgical oncology for hepatocellular carcinoma
    Takehiro Okabayashi, Motoyasu Tabuchi, Teppei Tokumaru +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Translational design of multifunctional novasomes for theranostic-driven precision therapy of cutaneous oncology.
    Md Azhar, Rishabha Malviya, Phool Chandra +4
    Journal of biological engineeringPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCPMC
  3. The Cholecystokinin-B Receptor as a Candidate Diagnostic Biomarker and Translational Target for Precision Oncology in Pancreatic Cancer
    Jill P. Smith
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  4. Revisiting Ehrlich carcinoma in the era of precision oncology: bridging classical models with modern systems biology.
    Varshini Manjunath, Rachana Rajesh Nayak, Ananth Koushik Bhujanga +2
    Medical oncology (Northwood, London, England)Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. Multimodal AI in Hepatocellular Carcinoma: Bridging Diagnosis, Therapy and Prognosis Toward Precision Oncology.
    Xinyi Chen, Fazhao Li, Yan Xu +3
    Journal of hepatocellular carcinomaPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lei2026chromophobe,
  title = {{Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease}},
  author = {Xiwen Lei and Rui Dong and Lijuan Yin and Zhenjie Wu and Linhui Wang and Miaoxia He},
  journal = {Journal of Translational Medicine},
  year = {2026},
  month = jul,
  doi = {10.1186/s12967-026-08668-z},
  url = {https://doi.org/10.1186/s12967-026-08668-z},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Chromophobe renal cell carcinoma: addressing the translational gap toward precision oncology for advanced disease
AU  - Xiwen Lei
AU  - Rui Dong
AU  - Lijuan Yin
AU  - Zhenjie Wu
AU  - Linhui Wang
AU  - Miaoxia He
PY  - 2026
DA  - 2026/07/28
JO  - Journal of Translational Medicine
DO  - 10.1186/s12967-026-08668-z
UR  - https://doi.org/10.1186/s12967-026-08668-z
AB  - Background: Chromophobe renal cell carcinoma (chRCC) represents a distinct histological subtype of kidney cancer. While typically characterized by an indolent clinical course, it presents significant management challenges in advanced or late-stage disease.  Main body of the abstract: This review presents current evidence regarding chRCC histopathology, emerging biomarkers, and proposed grading systems. We comprehensively analyze the molecular landscape, highlighting TP53 and PTEN mutations alongside characteristic chromosomal losses, while evaluating the role of epigenetic modifications and the immune microenvironment. Crucially, the paper details the mechanisms through which mitochondrial dysfunction and metabolic reprogramming drive chRCC pathogenesis. By assessing contemporary clinical trials, this work underscores the necessity for novel therapeutic interventions and the collection of large-scale prospective data to address current gaps in treatment.  Conclusion: A precision oncology framework for chRCC should prioritize reproducible diagnosis, cautious biomarker validation, and prospective rare-tumor trials to refine risk stratification and management.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12967-026-08668-z.
SN  - 1479-5876
ER  -